Multisystem Inflammatory Syndrome in U.S. Children and Adolescents
Understanding the epidemiology and clinical course of multisystem inflammatory syndrome in children (MIS-C) and its temporal association with Covid-19 is important, given the clinical and public health implications. Indeed, SARS-CoV-2 associated multisystem inflammatory syndrome has led to severe and life-threatening disease in previously healthy children and adolescents.
The study reports 186 MIS-C patients in 26 states. Cases were included based on 6 criteria: severe illness leading to hospitalization, age less than 21, fever lasting at least 24 hours, laboratory-proven inflammation, multisystem organ involvement, and evidence of SARS-CoV-2 infection ascertained with RT-PCR, antibody tests or exposure to people with Covid-19 in the past month.
- For further information: Multisystem Inflammatory Syndrome in Children in New York State
- July 20, 2020. JAMA. Should Coronavirus Disease 2019 – Associated Inflammatory Syndromes in Children Affect Social Reintegration?
Recent articles in several medical journals, including JAMA and the media in general have highlighted the emergence of inflammatory syndromes associated with coronavirus disease 2019 in children.
SARS-CoV-2 appears to induce this new condition, which has been called pediatric multisystem inflammatory syndrome (PIMS) or SARS-CoV-2 temporally associated pediatric multisystem inflammatory syndrome (PIMS-TS) and described in detail by European and international scientists. New York.
In addition, researchers in Italy have reported5 a dramatic increase in Kawasaki disease (KD), often associated with positive serological test results for COVID-19.
In summary, pediatric inflammatory syndromes presumably triggered by exposure to SARS-CoV-2 deserve greater awareness because they have critical, potentially life-altering outcomes for affected children.
In-depth research in this area is also absolutely necessary, as well as well-defined and uniform case definitions. However, unless there is a substantial increase in the number of cases in the coming months, these syndromes remain rare and should not be used to substantially change decisions affecting millions of schoolchildren. 9 July 2020.
Intensive care admissions of children with pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS) in the UK: a multicentre observational study
In April 2020, doctors in the UK observed unexplained inflammation in a group of children requiring admission to pediatric intensive care units (PICUs). The study describes the clinical features, course, management and outcomes of PICU patients with this condition, which is now known as SARS-CoV-2 temporally associated pediatric inflammatory multisystem syndrome (PIMS-TS). June 8, 2020 .
Clinical Characteristics of 58 Children With a Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2. What are the clinical and laboratory characteristics of critically ill children who developed multisystem inflammatory syndrome during the 2019 coronavirus pandemic?
In this series of hospitalized children who met the criteria for SARS-CoV-2 associated pediatric inflammatory multisystem syndrome, there is a broad spectrum of symptoms and disease severity, ranging from fever and inflammation to myocardial injury, shock and development of coronary artery aneurysms.
Comparison with patients with shock syndrome and Kawasaki disease provides insights into this syndrome and suggests that this disorder differs from other pediatric inflammatory entities.